Low expression of Mel-18 predicts poor prognosis in patients with breast cancer
Publication in refereed journal


摘要Background: Our previous study suggested that melanoma nuclear protein 18 (Mel-18) acted as a tumor suppressor in human breast cancer. This study was designed to investigate the clinical and prognostic significance of Mel-18 in breast cancer patients. Patients and methods: Mel-18 was detected by immunohistochemistry in paraffin-embedded tissues from 287 breast cancer patients, of which 287 were from primary cancer sites, 63 from matched adjacent noncancerous sites, and 35 from metastatic lymph nodes. Differences in Mel-18 expression and clinical characteristics were compared by χ2 test. Prognostic outcomes correlated with Mel-18 were examined using Kaplan-Meier analysis and Cox proportional hazards model. Results: The decreased Mel-18 expression is incremental depending upon the magnitude of cancer progression (P < 0.001). Mel-18 was conversely correlated with the pathological classifications (P < 0.001 for T, N, and M classifications, respectively), clinical staging (P < 0.001), and progesterone receptor (P = 0.030). Furthermore, patients with higher level of Mel-18 showed prolonged overall survivals (P < 0.001). The diminished Mel-18 expression may be a risk factor for the patients' survival (P < 0.001). Conclusions: Lower Mel-18 expression is correlated with advanced clinicopathologic classifications and a poor overall survival in breast cancer patients. These findings suggest that Mel-18 may serve as a useful marker in prognostic evaluation for patients. © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
著者Guo B.-H., Zhang X., Zhang H.-Z., Lin H.-L., Feng Y., Shao J.-Y., Huang W.-L., Kung H.-F., Zeng M.-S.
期刊名稱Annals of Oncology
詳細描述To ORKTS: Published online on 5 May 2010
出版社Oxford University Press
出版地United Kingdom
頁次2361 - 2369
關鍵詞Bmi-1, Breast cancer; Mel-18, Polycomb group proteins

上次更新時間 2021-24-09 於 23:35